Skip to main content

Gingival Recession

1
Pipeline Programs
4
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

CellTherX
CellTherXTX - Dallas
1 program
1
Markman Biologics Microsurfaced ADMPhase 41 trial
Active Trials
NCT04614350Completed10Est. Jun 2022
Geistlich Pharma
Geistlich PharmaSwitzerland - Root
4 programs
CAF+XCMN/A1 trial
Geistlich Fibro-GideN/A1 trial
MucograftN/A1 trial
experimental: collagen matrixN/A1 trial
Active Trials
NCT03833765Completed24Est. Jul 2017
NCT04260152Completed30Est. Jul 2020
NCT00902876Completed45Est. Jan 2012
+1 more trials
Organogenesis
OrganogenesisCANTON, MA
4 programs
CelTx™N/A1 trial
GintuitN/A1 trial
CelTxPHASE_1_21 trial
GintuitPHASE_31 trial
Active Trials
NCT01134081Completed44Est. Dec 2008
NCT01547962Completed25Est. May 2006
NCT00679081Terminated15Est. Sep 2010
+1 more trials
Zimmer Biomet
Zimmer BiometFL - Jacksonville
1 program
Puros® Dermis versus Alloderm®N/A1 trial
Active Trials
NCT00881959Completed80Est. Jun 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CellTherXMarkman Biologics Microsurfaced ADM
OrganogenesisGintuit
OrganogenesisCelTx
Geistlich PharmaGeistlich Fibro-Gide
Geistlich Pharmaexperimental: collagen matrix
Geistlich PharmaCAF+XCM
Zimmer BiometPuros® Dermis versus Alloderm®
Geistlich PharmaMucograft
OrganogenesisCelTx™
OrganogenesisGintuit

Clinical Trials (10)

Total enrollment: 389 patients across 10 trials

NCT04614350CellTherXMarkman Biologics Microsurfaced ADM

Pilot Study for Healing and Safety Outcomes in Gingival Recession

Start: Oct 2020Est. completion: Jun 202210 patients
Phase 4Completed

Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration

Start: Oct 2007Est. completion: Dec 200896 patients
Phase 3Completed

A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage

Start: May 2008Est. completion: Sep 201015 patients
Phase 1/2Terminated
NCT04260152Geistlich PharmaGeistlich Fibro-Gide

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

Start: Sep 2018Est. completion: Jul 202030 patients
N/ACompleted
NCT03344315Geistlich Pharmaexperimental: collagen matrix

Xenogeneic Collagen Matrix or Palatal Connective Tissue Graft With a Coronally Advanced Flap in Class III Recessions

Start: Mar 2017Est. completion: Jun 202020 patients
N/ACompleted

Adjunctive Benefit of a Xenogenic Collagen Matrix

Start: Nov 2012Est. completion: Jul 201724 patients
N/ACompleted
NCT00881959Zimmer BiometPuros® Dermis versus Alloderm®

Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®

Start: Aug 2009Est. completion: Jun 201280 patients
N/ACompleted

A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions

Start: Mar 2009Est. completion: Jan 201245 patients
N/ACompleted

Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts

Start: Jan 2008Est. completion: Dec 200844 patients
N/ACompleted

A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

Start: Sep 2005Est. completion: May 200625 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.